Business Models for Nucleotide Production in Highly Concentrated Markets: Approaches and Strategies for New Entrants

Abstract

The nucleotide market, essential for biotechnological and medical applications, is highly concentrated, with a small number of companies controlling production and commercialization. Entry barriers include technological, regulatory, and commercial restrictions that hinder new entrants. This study analyzes business models that could facilitate entry into this industry, focusing on nucleotide production from biomass as an innovative and sustainable alternative. Through an exploratory literature review and a comparative case analysis in high-tech markets, five strategic approaches are identified: 1) Niche strategy, targeting highly specialized segments with differentiated products; 2) Strategic collaborations, leveraging partnerships with universities and research centers to reduce costs and risks; 3) Value chain integration, aiming to minimize dependence on dominant suppliers by internalizing key processes; 4) Production innovation, emphasizing biomass-based methods to lower costs and enhance sustainability; and 5) Ingredient brand model, positioning nucleotides as a key input in final products without directly competing with established manufacturers. The study compares these approaches, highlighting their opportunities and threats, and discusses their applicability within the biotechnology sector. Finally, it underscores the need to assess the risks associated with entering oligopolistic markets and develop strategies to mitigate these challenges.